南微医学
(688029)
| 流通市值：155.46亿 | | | 总市值：155.46亿 |
| 流通股本：1.88亿 | | | 总股本：1.88亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,727,947,419.23 | 853,734,897.79 | 3,183,783,900.37 | 2,380,540,402.29 |
| 营业收入 | 1,727,947,419.23 | 853,734,897.79 | 3,183,783,900.37 | 2,380,540,402.29 |
| 二、营业总成本 | 1,348,475,630.82 | 670,832,383.74 | 2,480,891,306 | 1,755,895,594.02 |
| 营业成本 | 607,315,882.63 | 307,263,140.94 | 1,143,165,422.5 | 843,910,468.13 |
| 税金及附加 | 13,893,930.34 | 6,783,550.21 | 25,180,800.98 | 27,825,795.78 |
| 销售费用 | 365,370,647.99 | 171,872,994.88 | 745,962,430.56 | 519,284,587.78 |
| 管理费用 | 205,539,488.39 | 106,269,102.26 | 433,573,915.53 | 303,282,452.87 |
| 研发费用 | 98,251,622.03 | 46,768,414.51 | 199,046,344.86 | 133,829,765.81 |
| 财务费用 | 58,104,059.44 | 31,875,180.94 | -66,037,608.43 | -72,237,476.35 |
| 其中:利息费用 | 656,805.73 | 347,367.42 | 4,535,442.6 | 2,735,631.47 |
| 其中:利息收入 | 27,701,087.23 | 13,752,362.3 | 69,364,566.88 | 48,460,748.96 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 975,595.22 | 154,901.31 | 928,013.63 | 464,937.53 |
| 加:投资收益 | 7,610,395.57 | 3,260,591.96 | 16,942,047.43 | 10,014,502.83 |
| 资产处置收益 | 41,173.8 | 82,333.17 | 103,715.12 | 86,844.44 |
| 资产减值损失(新) | -10,803,100.29 | -3,008,258.03 | -42,513,477.38 | -14,868,324.93 |
| 信用减值损失(新) | -6,885,728.77 | -6,099,297.34 | -11,436,764.09 | -1,204,435.8 |
| 其他收益 | 7,276,357.38 | 4,337,477.12 | 24,773,209.19 | 7,171,881.93 |
| 四、营业利润 | 377,686,481.32 | 181,630,262.24 | 691,689,338.27 | 626,310,214.27 |
| 加:营业外收入 | 625,128.38 | 454,662.59 | 1,310,906.68 | 627,686.97 |
| 减:营业外支出 | 487,220.49 | 80,598.06 | 1,846,298.69 | 310,654.23 |
| 五、利润总额 | 377,824,389.21 | 182,004,326.77 | 691,153,946.26 | 626,627,247.01 |
| 减:所得税费用 | 69,356,355.03 | 33,281,533.66 | 108,596,296.24 | 96,536,905.89 |
| 六、净利润 | 308,468,034.18 | 148,722,793.11 | 582,557,650.02 | 530,090,341.12 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 308,468,034.18 | 148,722,793.11 | 582,557,650.02 | 530,090,341.12 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 303,425,747.12 | 146,462,686.25 | 570,327,371 | 509,263,960.74 |
| 少数股东损益 | 5,042,287.06 | 2,260,106.86 | 12,230,279.02 | 20,826,380.38 |
| 扣除非经常损益后的净利润 | 297,101,434.39 | 143,067,341.17 | 551,895,689.58 | 507,807,960.6 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.63 | 0.78 | 3.05 | 2.72 |
| (二)稀释每股收益 | 1.63 | 0.78 | 3.05 | 2.72 |
| 八、其他综合收益 | -71,631,554.82 | -41,562,531.58 | 50,506,340.71 | 29,811,229.06 |
| 归属于母公司股东的其他综合收益 | -63,971,124.16 | -38,028,480.82 | 41,339,237.51 | 24,041,064.39 |
| 九、综合收益总额 | 236,836,479.36 | 107,160,261.53 | 633,063,990.73 | 559,901,570.18 |
| 归属于母公司股东的综合收益总额 | 239,454,622.96 | 108,434,205.43 | 611,666,608.51 | 533,305,025.13 |
| 归属于少数股东的综合收益总额 | -2,618,143.6 | -1,273,943.9 | 21,397,382.22 | 26,596,545.05 |
| 公告日期 | 2026-08-27 | 2026-04-28 | 2026-04-28 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |